The RND3 antibody is a research tool designed to target the RND3 protein, also known as RhoE or Rho family GTPase 3. RND3 belongs to the Rho GTPase family, which regulates cytoskeletal dynamics, cell migration, proliferation, and apoptosis. Unlike classical Rho GTPases that cycle between active (GTP-bound) and inactive (GDP-bound) states, RND3 is considered an atypical member due to its constitutive GTPase activity and distinct regulatory mechanisms. It functions as a key mediator of cell signaling pathways, often opposing the effects of RhoA by inhibiting Rho-associated kinase (ROCK) activity. RND3 is implicated in diverse physiological processes, including neuronal development, vascular remodeling, and cancer progression. Studies highlight its role in suppressing tumor cell invasion, modulating epithelial-mesenchymal transition (EMT), and influencing neurodegenerative disorders. The RND3 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect RND3 expression levels, subcellular localization, and interactions in various tissues and disease models. Its application aids in understanding RND3's involvement in pathological conditions, such as glioblastoma, cardiovascular diseases, and Alzheimer's disease. Commercial RND3 antibodies are available from multiple suppliers, with validation data emphasizing specificity for human, mouse, or rat samples. Researchers often optimize protocols to address cross-reactivity or post-translational modification challenges, ensuring reliable results in both basic and translational studies.